<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704036</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00307525</org_study_id>
    <nct_id>NCT05704036</nct_id>
  </id_info>
  <brief_title>Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis</brief_title>
  <official_title>Transdermal Estradiol for Adolescent and Young Adult Women With CF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to learn about the role of estrogen in bone development in&#xD;
      adolescent and young adult women with cystic fibrosis (CF) and low estrogen levels. The main&#xD;
      questions it aims to answer are:&#xD;
&#xD;
        -  Is a study of transdermal estradiol (estrogen skin patches) feasible in this group?&#xD;
&#xD;
        -  How does transdermal estradiol impact bone health and quality of life?&#xD;
&#xD;
      Participants will apply transdermal estradiol patches (or placebo patches -- patches that&#xD;
      look like the estradiol patches but do not contain any estradiol) once weekly for 12 months,&#xD;
      fill out brief quality-of-life surveys twice per month, and complete blood draws and&#xD;
      questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The&#xD;
      participants will also have x-rays and DXAs (bone density assessment) performed at the&#xD;
      baseline and 12 month visits. Researchers will compare changes in various measurements&#xD;
      between the treatment and placebo groups to determine the impact of transdermal estradiol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of potential participants enrolled per month</measure>
    <time_frame>Evaluated monthly for 2 years, or until completion of study recruitment</time_frame>
    <description>Number of potential participants who complete screening visit per month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of screen fails</measure>
    <time_frame>Evaluated at completion of study recruitment, approximately one year</time_frame>
    <description>Percentage of potential participants who fail screening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study procedure completion rate</measure>
    <time_frame>Evaluated at completion of study, approximately two years</time_frame>
    <description>Percentage of participants enrolled in study who complete all study procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability as determined by participant report</measure>
    <time_frame>Across 12 months of study participation per participant</time_frame>
    <description>Acceptability during study participation by 5 point Likert scale, with a score or 3 or greater considered acceptable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum estradiol levels (pg/mL)</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>P1NP is a marker of bone turnover.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>CTX-1 is a marker of bone turnover.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>CFRSD-CRISS is a brief survey to assess quality of life of people with cystic fibrosis that will be taken by participants twice per month. The questionnaire is scored from 0-100 with higher scores indicating increased symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Hypoestrogenism</condition>
  <arm_group>
    <arm_group_label>Transdermal Estradiol/cyclic progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo transdermal estradiol/progesterone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will apply placebo transdermal estradiol patches weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take placebo progesterone for 10 days per month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estrogen</intervention_name>
    <description>Transdermal estradiol 0.1 mg/day, applied once weekly</description>
    <arm_group_label>Transdermal Estradiol/cyclic progesterone</arm_group_label>
    <other_name>Transdermal estradiol</other_name>
    <other_name>Climara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Placebo patch, applied once weekly</description>
    <arm_group_label>Placebo transdermal estradiol/progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive</description>
    <arm_group_label>Transdermal Estradiol/cyclic progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill daily for 10 days/month, if participant is not on progesterone-containing contraceptive</description>
    <arm_group_label>Placebo transdermal estradiol/progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CF diagnosis&#xD;
&#xD;
          -  16-30 years old&#xD;
&#xD;
          -  At least 2 years after first menstrual cycle&#xD;
&#xD;
          -  Low serum estradiol levels (&lt; 50 pg/mL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to transdermal estradiol&#xD;
&#xD;
          -  Current use of systemic estrogen (such as estrogen-containing oral contraceptive pill)&#xD;
&#xD;
          -  Previous lung or liver transplant&#xD;
&#xD;
          -  Use of chronic systemic glucocorticoids&#xD;
&#xD;
          -  Severe vitamin D deficiency (serum 25(OH)D &lt; 6 ng/mL)&#xD;
&#xD;
          -  Use of anti-osteoporosis therapy including anti-resorptives such as bisphosphonates or&#xD;
             anabolic agents such as teriparatide or denosumab&#xD;
&#xD;
          -  Conditions increasing risk of clot: history of previous deep vein thrombus or&#xD;
             pulmonary embolism, current immobility, current peripherally inserted central catheter&#xD;
             or mediport, known hypercoagulable condition&#xD;
&#xD;
          -  Baseline study visit falls between 1 and 8 weeks after initiation of CF transmembrane&#xD;
             receptor (CFTR) modulator&#xD;
&#xD;
          -  Currently in pulmonary exacerbation&#xD;
&#xD;
          -  Recent antibiotic use within the past 4 weeks for an acute pulmonary exacerbation&#xD;
&#xD;
          -  Pregnant, lactating, or planning to become pregnant during study&#xD;
&#xD;
          -  Unwilling or unable to use a non-estrogen containing method of contraception such as&#xD;
             barrier, abstinence, or progesterone-only method&#xD;
&#xD;
          -  In the opinion of the CF care team or study investigators participant should not&#xD;
             participate in the study&#xD;
&#xD;
          -  Inability to provide informed consent/assent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malinda Wu, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Malina</last_name>
    <phone>443-287-8997</phone>
    <email>smalina1@jh.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Malina</last_name>
      <phone>443-287-8997</phone>
      <email>smalina1@jh.edu</email>
    </contact>
    <investigator>
      <last_name>Malinda Wu, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>April 18, 2023</last_update_submitted>
  <last_update_submitted_qc>April 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Young Adult</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Premenopause</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Bone Disease</keyword>
  <keyword>Bone Diseases, Metabolic</keyword>
  <keyword>Hormones</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

